Management of Atrial Fibrillation with Rapid Ventricular Response

Initial Assessment and Management

The European Society of Cardiology recommends assessing hemodynamic stability immediately in patients with atrial fibrillation and rapid ventricular response, as those with hypotension, acute heart failure, or evidence of shock require emergent electrical cardioversion 3
Obtain a 12-lead ECG to confirm AF with RVR and evaluate for signs of ischemia, pre-excitation, or structural abnormalities, as recommended by the American College of Cardiology 4, 5
Perform transthoracic echocardiography to assess right ventricular function, valvular disease, and other structural abnormalities, as recommended by the American College of Cardiology 4, 5
Check laboratory tests including thyroid, renal, and hepatic function to identify potential triggers or comorbidities, as recommended by the American College of Cardiology 4

The European Society of Cardiology recommends beta-blockers as first-line therapy for patients with AF and reduced ventricular function (LVEF ≤40%), including right ventricular dysfunction 1, 2, 6
Digoxin can be used alone or in combination with beta-blockers in patients with ventricular dysfunction, as recommended by the European Society of Cardiology 2, 6
For patients with preserved RV function (LVEF >40%): Beta-blockers, diltiazem, verapamil, or digoxin can be used, as recommended by the European Society of Cardiology 6, 3
For patients with impaired RV function (LVEF ≤40%): Beta-blockers and/or digoxin only (avoid non-dihydropyridine calcium channel blockers like diltiazem and verapamil), as recommended by the European Society of Cardiology 6, 3
Target a lenient rate control strategy initially (resting heart rate <110 bpm), with stricter control if symptoms persist, as recommended by the European Society of Cardiology 6, 2

Assess stroke risk using CHA₂DS₂-VASc score, as recommended by the European Society of Cardiology 1, 7
Initiate anticoagulation for patients with CHA₂DS₂-VASc score ≥2 (men) or ≥3 (women), as recommended by the European Society of Cardiology 1, 7
Direct oral anticoagulants (DOACs) are preferred over vitamin K antagonists except in patients with mechanical heart valves or mitral stenosis, as recommended by the European Society of Cardiology 1, 8
Anticoagulation should be continued regardless of whether rhythm or rate control strategy is pursued, as recommended by the European Society of Cardiology 1, 7

Consider combination rate control therapy if a single drug fails to control symptoms or heart rate, as recommended by the European Society of Cardiology 6
For refractory cases, AV node ablation with pacemaker implantation may be considered, as recommended by the European Society of Cardiology 6, 2
In patients with heart failure and AF, cardiac resynchronization therapy should be considered following AV node ablation, as recommended by the European Society of Cardiology 6, 2
Rhythm control strategies (cardioversion, antiarrhythmic drugs, or ablation) may be considered for symptomatic patients despite adequate rate control, as recommended by the European Society of Cardiology 1, 7

Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil) in patients with right ventricular dysfunction as they can worsen heart failure, as warned by the European Society of Cardiology 6, 2
Do not discontinue anticoagulation if sinus rhythm is restored, as the risk of thromboembolism persists, as warned by the European Society of Cardiology 1, 7
Avoid combining antiplatelet therapy with anticoagulation unless specifically indicated (e.g., recent acute coronary syndrome) due to increased bleeding risk, as warned by the European Society of Cardiology 1, 3
Monitor for bradycardia when using combination rate control therapy, as recommended by the European Society of Cardiology 6
Regular reassessment of rate control adequacy and symptoms is essential for optimizing therapy, as recommended by the European Society of Cardiology 1, 6